Episode
Episode 482: Why the Framingham Heart Study Still Matters
- Published
- Feb 17, 2026
- Duration seconds
- 1462
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/heart-doc-vip-with-dr-joel-kahn-327754/episodes/episode-482-why-the-framingham-heart-study-still-matters/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/heart-doc-vip-with-dr-joel-kahn-327754/episode-482-why-the-framingham-heart-study-still-matters.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This week on Heart Doc VIP, Dr. Joel Kahn takes a deep dive into one of the most influential research projects in cardiovascular history: the Framingham Heart Study. Launched in 1948 and still going strong, this landmark study helped identify many of the risk factors we now take for granted, including smoking, diabetes, high cholesterol, high blood pressure, obesity, and physical inactivity. Much of what modern cardiology considers "common knowledge" about prevention started in Framingham. Dr. Kahn also explores practical and emerging topics in heart health, including the role of magnesium and berberine supplementation, how to approach both low-carb and low-fat diets in a healthy way, and concerns about long-term proton pump inhibitor use. Additional discussion covers EECP therapy and strategies to improve coronary blood flow, along with the potential benefits of ezetimibe for cholesterol reduction and brain health. Thank you to this week's sponsor, Igennus. Visit igennus.com and use code DRKAHN for a special discount.